Skip to main navigation
Pharvaris N.V logo
Main Menu

Header Nav

  • Our science
  • our pipeline
  • disease focus: HAE
  • HAE community
  • clinical trials
  • About us
    • about us
    • join us
    • Contact
  • Investors
Investor Menu

IR Nav

  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Financials
    • SEC Filings
  • Stock
    • Stock Performance
    • Analyst Coverage
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
  • Resources
    • FAQ
    • Contact Us
    • Email Alerts

Event Details

Breadcrumb

Home / Investor Relations / Events & Presentations / AAAAI Annual Meeting 2023

AAAAI Annual Meeting 2023

Feb 26, 2023 at 9:45 AM CST

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 1.1 MB
Dr. Marcus Maurer Audio Session (MP4) 6.3 MB
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Toolkit

Print Page
Print Page
Email Alerts
Email Alerts
IR Contacts
IR Contacts

Footer Links

Privacy     Cookie notice     Terms of Use

Social Links

  • Pharvaris 2020 - © All rights reserved